Combination drug therapy for advanced lung cancer after prior treatments
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination of two drugs (QL1706 and anlotinib) for people with advanced small cell lung cancer or squamous cell lung cancer who have already tried at least two earlier treatments. The goal is to see if this combination can help control the cancer when other options have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with small cell lung cancer or squamous cell lung cancer (a type of non-small cell lung cancer).
- You have already received at least two but no more than three previous treatments for your cancer.
- Your previous treatments included a platinum-based chemotherapy (like cisplatin or carboplatin) and a PD-1/PD-L1 immunotherapy drug (like pembrolizumab or nivolumab).
- You have tumors that can be measured on a CT scan, and your overall health is good enough to carry out daily activities (ECOG score 0 or 1).
- Your blood counts and organ functions (kidney, liver) are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (TQB2450), a targeted therapy (anlotinib), and chemotherapy for people with advanced non-small cell lung cancer whose cancer stopped responding to prior immunotherapy. It aims to find a new option when the first treatment didn't work anymore.
This trial tests a combination of two drugs, tislelizumab and anlotinib, for people with advanced non-small cell lung cancer that has progressed after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new combination of an immunotherapy drug (QL1706) with chemotherapy and a special radiation technique (Quad Shot) for people with advanced non-small cell lung cancer that has spread. The goal is to see if this combination can help control the cancer better than standard treatment.
This Phase 2 trial tests TQB2450 (a new cancer medicine) added to chemotherapy, or along with an oral medicine called anlotinib, for stage II–IIIB non-small cell lung cancer. It may help shrink tumors and improve outcomes in people who are getting curative surgery and have not had prior cancer drug treatment.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.